E. Läwitz

4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C

Paul Y. Kwo, E. Läwitz, Jonathan McCone et al. · Journal of Hepatology · 2009 · 86 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

Mark Sulkowski, David Gardiner, E. Läwitz et al. · Journal of Hepatology · 2012 · 80 citations

Medicine, Pharmacology, Pharmacotherapy +16

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

F. Poordad, E. Läwitz, K.V. Kowdley et al. · Journal of Hepatology · 2012 · 65 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION

Hendrik W. Reesink, H.L.A. Janssen, Stefan Zeuzem et al. · Journal of Hepatology · 2012 · 61 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

K.V. Kowdley, E. Läwitz, F. Poordad et al. · Journal of Hepatology · 2013 · 56 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +12